semaglutide deus medical Oral Weight-loss drug tied to lower

Expected Cholesterol Changes During GLP-1 Treatment Clinical data shows that patients on GLP-1 therapy see average reductions in LDL cholesterol of 10 to 15 percent within the first three months of consistent use

Food and Drug Administration (FDA) recommends patients prescribed semaglutide for weight loss start at a 0.25 mg dose and increase gradually to 2.4 mg over 16 to 20 weeks

Individuals with a BMI over 25 and metabolic symptoms, or a BMI over 30, may be considered for GLP-1 therapy following a medical evaluation

The PA criteria differ by diagnosis: For Type 2 diabetes indication: Documented Type 2 diabetes diagnosis (A1C 6.5% or fasting glucose 126 mg/dL) BMI 27 kg/m (this requirement appears in most UnitedHealthcare medical policies even for diabetes, though not an FDA requirement) Trial and failure of metformin for at least 90 days, unless contraindicated Trial and failure of at least one other oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days A1C remains 7.0% despite conventional therapy For obesity indication (when covered): BMI 30 kg/m, or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) Documented weight-loss attempts with behavioral modification and diet for at least 6 months No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2) Prescriber must be MD, DO, NP, or PA (some plans require endocrinologist or bariatric specialist) The PA approval timeline is 3 to 7 business days for standard requests, 24 hours for urgent requests